Filtered By:
Drug: Fortamet
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 9822 results found since Jan 2013.
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3).
CONCLUSIONS: Dulaglutide improves glycemic control and is well tolerated as monotherapy in patients with early stage type 2 diabetes.
PMID: 24842985 [PubMed - as supplied by publisher]
Source: Diabetes Care - May 19, 2014 Category: Endocrinology Authors: Umpierrez G, Povedano ST, Manghi FP, Shurzinske L, Pechtner V Tags: Diabetes Care Source Type: research
Risk of Lactic Acidosis or Elevated Lactate Concentrations in Metformin Users With Renal Impairment: A Population-Based Cohort Study.
CONCLUSIONS: Our study is consistent with current recommendations that the renal function of metformin users should be adequately monitored and that the dose of metformin should be adjusted, if necessary, if renal function falls below 60 mL/min/1.73 m(2).
PMID: 24842984 [PubMed - as supplied by publisher]
Source: Diabetes Care - May 19, 2014 Category: Endocrinology Authors: Eppenga WL, Lalmohamed A, Geerts AF, Derijks HJ, Wensing M, Egberts A, De Smet PA, de Vries F Tags: Diabetes Care Source Type: research
HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin.
CONCLUSION: Added to metformin, albiglutide was well-tolerated; produced superior reductions in HbA1c and FPG at week 104 compared with placebo, sitagliptin, and glimepiride; and resulted in weight loss compared with glimepiride.
PMID: 24898304 [PubMed - as supplied by publisher]
Source: Diabetes Care - June 4, 2014 Category: Endocrinology Authors: Ahrén B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C, Feinglos MN, for the HARMONY 3 Study Group Tags: Diabetes Care Source Type: research
Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial.
CONCLUSIONS: In this large study, individuals with diabetes who used metformin had a similar risk of developing cancer compared with those who used sulfonylureas.
PMID: 24898303 [PubMed - as supplied by publisher]
Source: Diabetes Care - June 4, 2014 Category: Endocrinology Authors: Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby D, Vineis P, Tzoulaki I, Ioannidis JP Tags: Diabetes Care Source Type: research
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro.
CONCLUSIONS: Weekly albiglutide is a simpler therapeutic option than thrice-daily lispro for advancing basal insulin glargine therapy, resulting in comparable HbA1c reduction with weight loss and lower hypoglycemia risk.
PMID: 24898300 [PubMed - as supplied by publisher]
Source: Diabetes Care - June 4, 2014 Category: Endocrinology Authors: Rosenstock J, Fonseca VA, Gross JL, Ratner RE, Ahrén B, Chow FC, Yang F, Miller D, Johnson SL, Stewart MW, Leiter LA, for the Harmony-6 Study Group Tags: Diabetes Care Source Type: research
Metformin and cancer: mounting evidence against an association.
PMID: 24963109 [PubMed - in process]
Source: Diabetes Care - June 27, 2014 Category: Endocrinology Authors: Suissa S, Azoulay L Tags: Diabetes Care Source Type: research
Efficacy and Safety of Oral Methazolamide in Patients With Type 2 Diabetes: A 24-Week, Placebo-Controlled, Double-Blind Study.
CONCLUSIONS: Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control.
PMID: 25125506 [PubMed - as supplied by publisher]
Source: Diabetes Care - August 14, 2014 Category: Endocrinology Authors: Simpson RW, Nicholson GC, Proietto J, Sarah A, Sanders KM, Phillips G, Chambers J, MacGinley R, Orford N, Walder K, Krippner G, Skoff K, Wacher VJ Tags: Diabetes Care Source Type: research
Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira).
CONCLUSIONS: IDegLira achieved glycemic control superior to that of IDeg at equivalent insulin doses without higher risk of hypoglycemia and with the benefit of weight loss. These findings establish the efficacy and safety of IDegLira and the distinct contribution of the liraglutide component.
PMID: 25114296 [PubMed - as supplied by publisher]
Source: Diabetes Care - August 11, 2014 Category: Endocrinology Authors: Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, Rodbard HW, and on behalf of the NN9068-3912 (DUAL-II) Trial Investigators Tags: Diabetes Care Source Type: research
Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women.
CONCLUSIONS: Long-term use of sulfonylureas was associated with a significantly higher risk of developing CHD among women with diabetes.
PMID: 25150157 [PubMed - as supplied by publisher]
Source: Diabetes Care - August 22, 2014 Category: Endocrinology Authors: Li Y, Hu Y, Ley SH, Rajpathak S, Hu FB Tags: Diabetes Care Source Type: research
Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study.
CONCLUSIONS: Canagliflozin provided durable glycemic improvements compared with glimepiride, and was generally well tolerated in patients with type 2 diabetes receiving background treatment with metformin over 104 weeks.
PMID: 25205142 [PubMed - as supplied by publisher]
Source: Diabetes Care - September 9, 2014 Category: Endocrinology Authors: Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, Millington D, Vercruysse F, Canovatchel W, Meininger G Tags: Diabetes Care Source Type: research
Are Sulfonylurea and Insulin Therapies Associated With a Larger Risk of Cancer Than Metformin Therapy? A Retrospective Database Analysis.
CONCLUSIONS: In a retrospective database analysis, taking into account potential time-related biases, no reduced cancer risk was found in metformin users. To clarify the association between diabetes medication and cancer risk, further well-designed observational studies and RCTs are needed.
PMID: 25336750 [PubMed - as supplied by publisher]
Source: Diabetes Care - October 21, 2014 Category: Endocrinology Authors: Kowall B, Rathmann W, Kostev K Tags: Diabetes Care Source Type: research
HbA1c as a Predictor of Diabetes and as an Outcome in the Diabetes Prevention Program: A Randomized Clinical Trial.
CONCLUSIONS: HbA1c predicted incident diabetes. In contrast to the superiority of the lifestyle intervention on glucose-defined diabetes, metformin and lifestyle interventions had similar effects in preventing HbA1c-defined diabetes. The long-term implications for other health outcomes remain to be determined.
PMID: 25336746 [PubMed - as supplied by publisher]
Source: Diabetes Care - October 21, 2014 Category: Endocrinology Authors: Diabetes Prevention Program Research Group,* prepared by, Knowler WC, Edelstein SL, Goldberg RB, Ackermann RT, Crandall JP, Florez JC, Fowler SE, Herman WH, Horton ES, Kahn SE, Mather KJ, Nathan DM Tags: Diabetes Care Source Type: research
The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
CONCLUSIONS: As insulin was advanced earlier in therapy in the two-stage and single-stage approaches, patients reaching their A1c targets increased, severe hypoglycemic events increased, and diabetes-related complications and mortality decreased. Cost savings were estimated for 3 (of 4) strategies in the single-stage approach. Delays in treatment escalation substantially reduced patients reaching target A1c levels and increased the occurrence of major nonhypoglycemic diabetic complications. With the exception of substantial increases in severe hypoglycemic events, earlier use of insulin mitigates the clinical consequences ...
Source: Journal of Managed Care Pharmacy - November 14, 2014 Category: Drugs & Pharmacology Tags: J Manag Care Pharm Source Type: research
Development of heart failure in medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
CONCLUSIONS: Compared with metformin, there may be higher risk of developing HF in Medicaid patients started on rosiglitazone but not pioglitazone. While pioglitazone was associated with a lower risk of developing HF compared with rosiglitazone, health care professionals should continue to work closely with their patients to determine the treatment options most appropriate.
PMID: 25166288 [PubMed - in process]
Source: Journal of Managed Care Pharmacy - November 14, 2014 Category: Drugs & Pharmacology Tags: J Manag Care Pharm Source Type: research
The Effect of Metformin on Glucose Homeostasis During Moderate Exercise.
CONCLUSIONS: Metformin has a positive effect on glucose homeostasis during exercise.
PMID: 25468944 [PubMed - as supplied by publisher]
Source: Diabetes Care - December 2, 2014 Category: Endocrinology Authors: Hansen M, Palsøe MK, Helge JW, Dela F Tags: Diabetes Care Source Type: research
